JamieEChaftMD

Thoracic Cancer

Associate Attending Physician, Memorial Sloan-Kettering Cancer Center

Overview of Dr. Chaft

Dr. Jamie Chaft is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Sloan Kettering Monmouth. She received her medical degree from New York University Grossman School of Medicine and has been in practice 11 years. Dr. Chaft accepts several types of health insurance, listed below. She is one of 497 doctors at Memorial Sloan Kettering Cancer Center and one of 14 doctors at Memorial Sloan Kettering Monmouth who specialize in Oncology. She has more than 100 publications and over 500 citings.

Office
530 East 74th Street
New York, NY 10021
Book by Phone+1(847) 754-4259

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2006 - 2009
New York University School of MedicineClass of 2006

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2017 - 2025
NY State Medical License 2008 - 2025
NC State Medical License 2020 - 2022
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation Start of enrollment: 2008 Apr 01
Completed
Phase 2
Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN) Start of enrollment: 2011 Oct 01
Completed
Phase 2
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation Start of enrollment: 2013 Apr 01
Withdrawn
Phase 1
Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Start of enrollment: 2013 Oct 28
Terminated
Phase 1
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Start of enrollment: 2014 Mar 27
Completed
Phase 3
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC Start of enrollment: 2014 Sep 01
Active, not recruiting
Phase 2
Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer Start of enrollment: 2019 Jul 19
Active, not recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Association of the time of day of chemoradiotherapy and durvalumab with tumor control in lung cancer.
Matthew T McMillan, Annemarie Shepherd, Alissa J Cooper, Adam J Schoenfeld, Abraham J Wu
Radiotherapy and Oncology. 2024-12-01
Divergent clinical and immunologic outcomes based on STK11 co-mutation status in resectable KRAS-mutant lung cancers following neoadjuvant immune checkpoint blockade.
Samuel Rosner, Sydney Connor, Khaled Sanber, Marianna Zahurak, Tianbei Zhang
Clinical Cancer Research. 2024-11-15
A Promising Step Forward With Giant Leaps Ahead.
Narek Shaverdian, Bob T Li, James Isbell, Jamie E Chaft
Journal of Thoracic Oncology. 2024-10-01

Journal Articles

Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients with Metastatic EGFR-Mutant Lung Cancers
Helena A Yu, Adam J Schoenfeld, Jamie E Chaft, Gregory J Riely, JAMA Oncology
Differential Regulation of PD-L1 Expression by Immune and Tumor Cells in NSCLC and the Response to Treatment with Atezolizumab (Anti–PD-L1)
Alan Sandler, David S Shames, Hartmut Koeppen, Jamie Chaft, Scott N Gettinger, Alexander Spira, Daniel S Chen, Naiyer A Rizvi, David R Spigel, Proceedings of the National Academy of Sciences
Pathologic Features of Response to Neoadjuvant Anti-PD-1 in Resected Non-Small Cell Lung Carcinoma: A Proposal for Quantitative Immune-Related Pathologic Response Crit...
J M Isbell, N Rekhtman, J D Wolchok, J E Chaft, Annals of Oncology
YES1 Amplification Is a Mechanism of Acquired Resistance to EGFR Inhibitors Identified by Transposon Mutagenesis and Clinical Genomics
Emmet J Jordan, Helena A Yu, Yelena Y Janjigian, Mark G Kris, Paul K Paik, Jamie E Chaft, Lu Wang, Gregory J Riely, Proceedings of the National Academy of Sciences
Join now to see all

Lectures

Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC.
2019 ASCO Annual Meeting - 6/1/2019
EA5142 adjuvant nivolumab in resected lung cancers (ANVIL).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

Updated 5-Year Data from the IMpower010 TrialSeptember 17th, 2024
Moving Immunotherapy into the Treatment of Resectable Non–Small Cell Lung CancerJune 1st, 2024
Moving the Goal Posts for Pre-Op and Post-Op Chemotherapy for Resectable NSCLCJuly 8th, 2022
Join now to see all

Insurance Accepted

GHI PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment